Skip to content
Screener

Incyte INCY Total Revenue

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
Pfizer logo
PfizerPFE
$15.03B+2.6%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$22K-97.0%
Gilead Sciences logo
Gilead SciencesGILD
$7.8B+10.2%
Geron logo
GeronGERN
$57.48M+17.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$213.48M+3,749%

Segments

By product

See full
JAKAFI$816.66M+6.9%
OPZELURA$449.74M+173%
JAKAVI Royalty Revenues$124.19M+13.2%
NIKTIMVO$60.31M+66.8%
MINJUVI/MONJUVI$53.69M+72.5%
ZYNYZ$49.95M+460%

By geography

See full
Europe$105.13M+33.4%
Other countries$8.8M+102%

By segment

See full
Reportable Segment$1.67B+37.7%

Other financials

Income statement

See full
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.29B+52.7%
Enterprise value$21.34B+45.7%
P/E15.7×-3.3×
P/S4.4×+0.7×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net sales$1,488,149$1,059,414$2,592,633$1,981,688
Product royalty revenues174,690151,115325,882281,739
Milestone and contract revenues11,2005,00028,2005,000
Total revenues1,674,0391,215,5292,946,7152,268,427
Costs, expenses and other:
Cost of sales (including definite-lived intangible amortization)104,95778,766209,480151,954
Contract dispute settlement(242,251)(242,251)
Research and development516,950494,9171,032,853932,196

Item 1. Financial Statements

FAQ

What is Incyte's total revenue?
Incyte (INCY) reported total revenue of $1.67B in Q2 2026.
How has Incyte's total revenue changed year-over-year?
Incyte's total revenue increased by 37.7% year-over-year, from $1.22B to $1.67B.
What is the long-term trend for Incyte's total revenue?
Over 4 years (2021 to 2025), Incyte's total revenue has grown at a 14.5% compound annual growth rate (CAGR), from $2.99B to $5.14B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Incyte's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude